Free shipping on all orders over $ 500

Ivosidenib

Cat. No. M8958

All AbMole products are for research use only, cannot be used for human consumption.

Ivosidenib Structure
Synonym:

AG-120

Size Price Availability Quantity
10mM*1mL in DMSO USD 110 In stock
1mg USD 30 In stock
5mg USD 66 In stock
10mg USD 120 In stock
25mg USD 200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG).

In vitro, TF-1 cells or primary human AML patient samples expressing mutant IDH1 are treated with AG-120.Treatment with AG-120 decreases intracellular 2-HG levels, inhibites growth factor independent proliferation and restores erythropoietin (EPO)-induced differentiation in TF-1 IDH1-R132H cells.

Protocol (for reference only)
Cell Experiment
Cell lines TF-1 cells
Preparation method TF-1 cells or primary human AML patient samples expressing mutant IDH1 are treated with AG-120.
Concentrations 0.5, 1.0, and 5.0 μM
Incubation time 6 days
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 582.96
Formula C28H22ClF3N6O3
CAS Number 1448347-49-6
Solubility (25°C) DMSO: ≥ 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Popovici-Muller J, et al. ACS Med Chem Lett. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

Related Isocitrate Dehydrogenase (IDH) Products
AGI-5198

AGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 μM and 0.16 μM, respectively.

AGI-6780

AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.

Enasidenib

Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.

BAY-1436032

BAY1436032 is a novel pan-mutant IDH1 inhibitor, it specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells.

GSK864

GSK864 is a cell penetrant, potent and selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) that potently inhibits intracellular 2-hydroxyglutarate (2-HG) production in HT-1080 cells.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ivosidenib, AG-120 supplier, Isocitrate Dehydrogenase (IDH), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.